Financière de Tubize SA SMA 200
What is the SMA 200 of Financière de Tubize SA?
The SMA 200 of Financière de Tubize SA is €99 +23.27%
What is the definition of SMA 200?
SMA 200 is an average stock price from the last 200 days calculated as an unweighted mean of the previous 200 stock closing prices.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 of companies in the Health Care sector on EURONEXT compared to Financière de Tubize SA
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Companies with sma 200 similar to Financière de Tubize SA
- Michelmersh Brick Plc has SMA 200 of GBX99 +0.61%
- U.S. Physical Therapy has SMA 200 of $99 -18.88%
- adesso AG has SMA 200 of €99 -70.91%
- Jagran Prakashan has SMA 200 of ₨99 +7.80%
- Insperity Inc has SMA 200 of $99 -14.90%
- Marwyn Value Investors has SMA 200 of GBX99 -5.44%
- Financière de Tubize SA has SMA 200 of €99 +23.27%
- Marwyn Value Investors has SMA 200 of GBX99 +57.44%
- Jagran Prakashan has SMA 200 of ₨99 +6.99%
- Restaurant Brands International has SMA 200 of CAD$99 -6.10%
- iShares VI Public - iShares Euro Corporate Bond s UCITS ETF has SMA 200 of €99 +1.58%
- Akamai Technologies has SMA 200 of $99 -3.75%
- Akamai Technologies Inc has SMA 200 of $99 -2.74%